$BST

BlackRock Runs a Tech Fund That Pays 6% Monthly, Is Up 39% This Year, and Trades at a 6% Discount

BlackRock Science and Technology Trust (BST) and its sibling, BlackRock Science and Technology Term Trust (BSTZ), are closed-end funds focused on tech. BST offers a 5.9% yield, a 31.28% YTD return, and trades at a 3.93% discount. BSTZ provides a higher 6.2% yield, a 46.59% YTD return, and a 6.2% discount, with a planned liquidation in 2031. BSTZ's portfolio has a heavier tilt toward private companies and higher fees.

Original reporting
Published Sep 10, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 10:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BlackRock Runs a Tech Fund That Pays 6% Monthly, Is Up 39% This Year, and Trades at a 6% Discount — source image
Decision brief

The 30-second read

$BSTNeutralLow
01

Why it matters

Provides traders with a side‑by‑side assessment to decide between a perpetual fund (BST) and a term fund (BSTZ).

02

Market read

Offers actionable insight for income‑oriented investors evaluating tech‑focused CEFs.

03

What to watch

Potential tax implications of swapping funds and the impact of private‑company valuations.

Relevance 4/10Novelty 2/10Timing: as of September 2026

Background

The piece compares two BlackRock tech closed‑end funds, focusing on yield, discount, and portfolio composition.

Company-level read

Ticker impact

$BSTNeutralMedium confidence
Context

Article details BST's current discount, yield and YTD performance, providing fresh data for traders.

Expected impact

Potential modest price appreciation if discount compresses; otherwise flat.

Evidence & confidence

Yield is attractive but fee drag and discount limit upside; no new catalyst.

$BSTZBullishMedium confidence
Context

Article highlights BSTZ's larger discount, higher yield and 2031 termination date, a structural catalyst.

Expected impact

Discount may narrow as 2031 approaches, supporting price gains.

Evidence & confidence

Structural discount and higher yield provide a clear investment angle.

Market effects

Highlights continued investor interest in tech‑focused closed‑end funds and AI exposure.

U.S. income‑focused investors may re‑allocate between BST and BSTZ.

Limited; primarily affects niche fund investors.

Counterpoint

The higher expense ratio and private‑asset risk in BSTZ may outweigh discount benefits.

Key entities

  • BlackRock Science and Technology Trust

    Ticker BST, perpetual closed‑end fund.

  • BlackRock Science and Technology Term Trust

    Ticker BSTZ, term closed‑end fund maturing 2031.

Related articles

$GFSMed

Stifel reiterates GlobalFoundries stock rating on Japan fab deal

Stifel reiterated a Buy rating and $60 price target on GlobalFoundries (GFS) after its Japan fab deal. The company will operate two 300mm facilities funded by up to $21B from Japan, with the first facility expected in 2029. GFS projects long-term EPS accretion of $0.50-$0.75 from the first facility. Analysts show strong conviction, with consensus targets pointing to 53% upside potential.

$MIRMMed

Stifel raises Mirum Pharmaceuticals stock price target on approvals

Stifel raised its price target for Mirum Pharmaceuticals (MIRM) to $156 from $136, citing recent clinical and regulatory achievements. The stock trades at $82.64, with strong revenue growth of 44% over the last year, reaching $618 million. Analysts highlight multiple expansion opportunities and a potential peak portfolio value of over $4 billion. The stock has declined 17% over the past six months, but analysts maintain a positive outlook.

$TMLow

Toyota’s AU$750M DPF Payout: What HiLux, Prado and Fortuner Owners Get

Toyota Australia agreed to a AU$750 million settlement for class actions over diesel particulate filter (DPF) issues in HiLux, Prado, and Fortuner models, pending court approval. The settlement covers 264,170 vehicles sold between 2015 and 2020, with defects reducing vehicle value. Toyota Motor Corporation stated the payout is immaterial to its finances.

$KRYSMedAI 8/10

Krystal Biotech Reports KB113 Lesion Regression in Gorlin Syndrome Pilot Study as FDA Discussions Begin

Krystal Biotech (NASDAQ:KRYS) reported that its investigational immunotherapy KB113 showed regression in 83% of assessed basal cell carcinoma lesions in a pilot study of three Gorlin syndrome patients. The company has begun FDA discussions for further development. Biopsies confirmed complete responses in three lesions. The study is small and preliminary, with larger trials needed to confirm efficacy and safety.